These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38276008)

  • 1. Harmaline to Human Mitochondrial Caseinolytic Serine Protease Activation for Pediatric Diffuse Intrinsic Pontine Glioma Treatment.
    Miciaccia M; Rizzo F; Centonze A; Cavallaro G; Contino M; Armenise D; Baldelli OM; Solidoro R; Ferorelli S; Scarcia P; Agrimi G; Zingales V; Cimetta E; Ronsisvalle S; Sipala FM; Polosa PL; Fortuna CG; Perrone MG; Scilimati A
    Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38276008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
    Gardner SL; Tarapore RS; Allen J; McGovern SL; Zaky W; Odia Y; Daghistani D; Diaz Z; Hall MD; Khatib Z; Koschmann C; Cantor E; Kurokawa R; MacDonald TJ; Aguilera D; Vitanza NA; Mueller S; Kline C; Lu G; Allen JE; Khatua S
    Neurooncol Adv; 2022; 4(1):vdac143. PubMed ID: 36382108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective.
    Perrone MG; Ruggiero A; Centonze A; Carrieri A; Ferorelli S; Scilimati A
    Curr Med Chem; 2021; 28(17):3287-3317. PubMed ID: 32767913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
    Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP
    J Neurosurg Pediatr; 2019 Apr; 23(6):719-725. PubMed ID: 30952114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
    Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Grand ML; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
    Cancer Res; 2023 May; ():OF1-OF17. PubMed ID: 37195023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
    Duchatel RJ; Mannan A; Woldu AS; Hawtrey T; Hindley PA; Douglas AM; Jackson ER; Findlay IJ; Germon ZP; Staudt D; Kearney PS; Smith ND; Hindley KE; Cain JE; André N; La Madrid AM; Nixon B; De Iuliis GN; Nazarian J; Irish K; Alvaro F; Eisenstat DD; Beck A; Vitanza NA; Mueller S; Morris JC; Dun MD
    Neurooncol Adv; 2021; 3(1):vdab169. PubMed ID: 34988452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased natural killer cells in diffuse intrinsic pontine glioma patients.
    Zhang L; Yu H; Xue Y; Liu Y
    Childs Nerv Syst; 2020 Jul; 36(7):1345-1346. PubMed ID: 32418048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
    Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdés-Mora F; Rakotomalala A; Meignan S; Pasquier E; Andre N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
    Cancer Res; 2023 May; 83(14):2421-37. PubMed ID: 37145169
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Kluiver TA; Alieva M; van Vuurden DG; Wehrens EJ; Rios AC
    Front Oncol; 2020; 10():92. PubMed ID: 32117746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate Profiling of Mitochondrial Caseinolytic Protease P via a Site-Specific Photocrosslinking Approach.
    Nguyen TA; Gronauer TF; Nast-Kolb T; Sieber SA; Lang K
    Angew Chem Int Ed Engl; 2022 Mar; 61(10):e202111085. PubMed ID: 34847623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
    Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
    Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.
    Amani V; Prince EW; Alimova I; Balakrishnan I; Birks D; Donson AM; Harris P; Levy JM; Handler M; Foreman NK; Venkataraman S; Vibhakar R
    BMC Cancer; 2016 Aug; 16():647. PubMed ID: 27538997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of tumor growth and post-irradiation recurrence in a diffuse intrinsic pontine glioma mouse model.
    Caretti V; Zondervan I; Meijer DH; Idema S; Vos W; Hamans B; Bugiani M; Hulleman E; Wesseling P; Vandertop WP; Noske DP; Kaspers G; Molthoff CF; Wurdinger T
    Brain Pathol; 2011 Jul; 21(4):441-51. PubMed ID: 21159008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies.
    Liu G; Qiu Y; Zhang P; Chen Z; Chen S; Huang W; Wang B; Yu X; Guo D
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
    Vitanza NA; Monje M
    Curr Treat Options Neurol; 2019 Jul; 21(8):37. PubMed ID: 31290035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.